Human gliomas were imaged in vivo using ligands for the peripheral-type benzodiazepine binding site ( A technique for imaging the extent and viability of a ghoma without depending on abnormal permeability of the blood-brain barrier would be of great value in the diagnosis and management of tumor. At present the diagnosis and treatment of gliomas rely primarily on x-ray computed tomography (CT) and magnetic resonance imaging (MRI). The contrast enhancement typically present in high-grade gliomas with CT or MRI and contrast agents delineates a region of increased permeability of the blood-brain barrier that correlates well with the solid tumor mass {l-61. However, CT is often unsatisfactory for demonstrating tumor regions with normal permeability of the bloodbrain barrier, including most low-grade gliomas and the infiltrating portions of high-grade gliomas 11-47.
A technique for imaging the extent and viability of a ghoma without depending on abnormal permeability of the blood-brain barrier would be of great value in the diagnosis and management of tumor. At present the diagnosis and treatment of gliomas rely primarily on x-ray computed tomography (CT) and magnetic resonance imaging (MRI). The contrast enhancement typically present in high-grade gliomas with CT or MRI and contrast agents delineates a region of increased permeability of the blood-brain barrier that correlates well with the solid tumor mass {l-61. However, CT is often unsatisfactory for demonstrating tumor regions with normal permeability of the bloodbrain barrier, including most low-grade gliomas and the infiltrating portions of high-grade gliomas 11-47.
MRI reveals a more extensive abnormality than CT but cannot reliably distinguish tumor from peritumoral edema C4-77. Neither technique can accurately differentiate gliomas from other tumors such as brain metastases, and neither can distinguish viable tumor from largely necrotic tumor 17, 8) .
A promising approach to imaging gliomas employs radiolabeled ligands for the peripheral-type benzodiazepine binding site (PBBS), also known as the 0 3 binding site (9). The "peripheral" notation indicates that this site is normally present in highest density in certain tissues outside the central nervous system (CNS) including the adrenal gland, lung, kidney, heart, and skin {lo]. Selective ligands for the PBBS include the benzodiazepine Ro5-4864 and the isoquinoline derivative PK 11 195, while nonselective ligands including the benzodiazepine flunitrazepm bind to the PBBS but also to central benzodiazepine receptors. The PBBS is present in low density in the normal brain and is thought to be located primarily on glia rather than on neurons { 1 1-14).
Several studies indicate that the PBBS is present on gliomas in high density. Specific binding to the PBBS is greatly increased in C6 rat gliomas and U87 human gliomas implanted in rat brains and studied in vitro and in vivo [lo] . In vivo accumulation of PBBS ligands in gllomas in rats can be blocked with unlabeled ligand, indicating that it depends o n specific binding rather We investigated the imaging of human gliomas in vivo using positron emission tomography (PET) with radiolabeled Ro5-4864 and PK 11 195.
Methods Patients
Five patients with gliomas were scanned with ["C]Ro5-4864. All had astrocytomas grade I1 (astrocytoma), I11 (anaplastic astrocytoma), or IV (glioblastoma) according to the diagnostic criteria of the World Health Organization 1181, but two of the tumors also contained regions of oligodendroglioma. Three patients had been treated with radiotherapy, and one of these had received chemotherapy. Ten patients with astrocytomas were scanned with ["CIPK l 1195. Nine had astrocytomas grade 11,111, or IV, and one had an astrocytoma that could not be assigned a grade. Seven patients had been treated with radiotherapy, and 4 of these had also received chemotherapy. These studies were approved by the institutional review board, and informed consent was obtained from all patients.
Positron Emission Tomography
[l1C)Ro5-4864 and { "C]PK 11 195 were synthesized by Nalkylation of their desmethyl precursors using I"C7methyl iodide. Ro5-4864 is 4'-chlorodiazepam, or 7-chloro-5-(4-chloropheny1)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one. PK 11 195 is 1-(2-chlorophenyl)-N-methyl-N-(1 -methylpropyl)-3-isoquinolinecarboxamide. {11C]Ro5-4864 was prepared using a captive solvent method 1191, and {"CIPK 11 195 was prepared and purified using the method of Camsonne and colleagues 1207, with minor modifications. Radiochemical purities were greater than 99%, and specific activities at injection ranged from 30 to 156 mCi/pmoI for [1'C)Ro5-4864 and 20 to 193 mCi/kmol for ["C]PK 11195. Injected doses were 15 mCi of [11C}Ro5-4864 and 24 mCi of fl'C}PK 11 195, in most patients.
PET was performed using a PCT 4600A tomograph, which has a resolution of 1.1 x 1.1 x 0.95 cm. Five planes with center-to-center spacing of 1.15 cm are scanned simultaneously with this tomograph. A dynamic series of 7 or more PET frames of progressively increasing duration was recorded over 80 minutes. In 3 patients scanned with C1'C1R05-4864 and 4 with E1' C]PK 11 195, a minimum of 16 PET frames were recorded over 80 minutes, and sequential arterial blood samples were obtained at 5-to 10-second intervals during the first 2 minutes and less frequently thereafter for measurement of radioactivity. For the ["C}R05-4864 scans, hydrophilic metabolites were isolated from blood by CIS reverse-phase SepPak column chromatography (Waters Associates, Milford, MA). In patients who underwent arterial blood collection, dynamic scans of local blood flow were also performed at the same brain levels after intravenous injection of [1501~20 l217.
Regions of interest that were defined represented tumor, gray matter, and white matter. For tumor, we used an approach designed to define regions of interest encompassing the portions of tumor with relatively high activity on scans at 40 to 80 minutes after injection. First, the tumor was delineated in either one or two planes on the CT scan, and these regions were mapped to the PET scans using a planimetric approach. Second, within these regions we determined the average pixel value in the highest 5% of pixels, and all pixels with values greater than 75% of that value were included within the F o r region of interest. This approach generated contiguous regions of interest averaging 8.6 f 9.4 cm2 in area for ["C]Ro5-4864 scans and 8.6 5 6.9 cm2 for ["CIPK 11195 scans. These regions encompassed 59 f 23% of the total area of the CT-mapped region for {"C]Ro5-4864 scans and 66 k 23% for ["CIPK 11195 scans. Regions representing gray matter were defined on 0-to 5-minute scans as a 1.1-cm-thick band following the peak radioactivity in contralateral frontal, temporoparietal, and calcarine cortex and as a 1.1 X 1.5-cm ellipse over the peak radioactivity for thalamus. Regions representing white matter were defined in the centrum semiovale above the level of the lateral ventricle. Correlations of regional radioactivity or radioactivity ratios with specific activity were performed using the nonparametric Spearman rank test.
In the patients who underwent arterial blood sampling, the In Vitro A.vtoradiogrupby Sections (6 pn) from frozen specimens taken at biopsy were thaw-mounted onto gelatin-coated slides. The sections were prewashed three times for 5 minutes each in 5 mM tris-HC1 buffer, pH 7.4, and then incubated for 60 minutes at 4°C in the same buffer containing either 1 nM E3H)PK 11 195 or 2 nM f3H}Ro5-4864. Unlabeled ligand (10 pM) was added for incubation of the blanks. The sections were postwashed three times for 5 minutes each in cold buffer, dried in a stream of cool air, placed in x-ray cassettes with radioactive standards, and apposed to Ultrofilm 3H (LKB, Bromma, Sweden) for 2 weeks at 4°C. The resulting images were analyzed by computer-assisted densitometry 1231. Statistical analysis was performed using the two-tailed paired sample t test on logarithmically transformed data.
ResuIts
T h e images from the first several minutes after injection of ["C]Ro54864 (Fig 1) resembled the blood flow images, with radioactivity (per unit volume) in the gray matter being higher than that in the tumor, which was higher than that in the white matter. Late images showed accumulation of radioactivity in white matter, with radioactivity in the white matter being higher than that in gray matter, which was higher than the radioactivity in the tumor. The ratio of radioactivity in tumor to that in remote gray matter at 60 to 80 minutes averaged 0.72 0.15 (mean ? SD). In no case did tumor achieve higher radioactivity than gray matter or white matter in late images. The results of kinetic analysis indicated that blood vessels in tumor and brain were permeable to [l1C)Ro5-4864 (Table 1) . One or more hydrophilic metabolites accounted for 54 2 11% (mean -C SD) of the radioactivity in blood at 80 minutes after injection.
The unexpected imaging results with [11c}Ro5-4864 prompted us to examine binding to the PBBS in vitro in 3 human grade I11 or IV astrocytoma taken at biopsy specimens [ 181. The specimens displayed little binding of E3C}Ro5-4864, and the majority of the binding was nonspecific (Table 2, Fig 2) . In contrast, specific binding of 13H)PK 11195 was high and significantly exceeded binding of E3H]Ro5-4864.
After obtaining these in vitro results, we imaged patients with gliomas using I1'C}PK 11195 (Fig 3) . In the early images radioactivity was approximately equal in the gray matter and tumor and higher in both of these regions than in the white matter. High radioactivity was also noted in large venous structures. In 8 of 10 patients, the late images showed a visually recognizable pattern pf increased radioactivity in tumor'. Radioactivity in the 60-to 80-minute images was hghest in the tumor, which had more radioactivity than gray matter, which in turn had more than the white matter. The ratio of radioactivity in tumor to that in remote gray matter typically reached a plateau at approximately 40 minutes. At 60 to 80 minutes, the tumor/ gray matter ratio was 1.41 5 0.39 (mean f . SD) ( Table 3 ). The tumodgray matter ratio averaged 1.75
? 0.18 in 5 patients studied at specific activities of 123 to 193 mCi/pmol and 1.08 2 0.17 in 5 patients studied at specific activities of 20 to 52 mCi/pmol. For comparison, the tumor/gray matter ratios measured using the entire CT-mapped regions were 1.29 ? 0.41
for the entire group, 1.61 2 0.29 for the 5 patients studied at higher specific activity, and 0.96 f. 0.17 for those studied at lower specific activity. The specific activity at injection correlated with the tumodgray matter ratio ( p < 0.02) and with the tumor/white matter ratio ( p < 0.01). The specific activity also correlated with absolute tumor radioactivity at 60 to 80 (Table 4 ). In the 7 tumors delineated on CT by contrast enhancement, high {llC}PK 11 195 radioactivity was seen in a configuration similar to the enhancement, but in 2 of these tumors, high radioactivity extended into areas without contrast enhancement. Only 1 tumor without contrast enhancement was studied at high specific activity, and that tumor had a tumor/gray matter ratio of 1.88 (see Fig 3) .
PBBS in human gliomas studied in vitro with autoradiography and in vivo with PET are similar to those of human glloma cell lines studied in culture 1161 but different from those of human gliomas implanted in athymic rats, where both PK 11195 and Ro5-4864 bind avidly 1151. The milieu of the rat brain may cause the properties of the PBBS in implanted gliomas to differ from those expressed in ghomas in the human brain or in human gliomas in cell culture.
Langer and Arbilla 191 proposed a new nomenclature in which the subtypes of central benzodiazepine receptors are renamed the w1 and w2 sites and the PBBS is renamed the w3 site. Among the reasons for renaming the PBBS are the arguments that drugs other than benzodiazepines, including the isoquinoline PK 11195, are lgands for the PBBS and that the PBBS is expressed in the CNS as well as at peripheral sites. On the other hand, one possible explanation for our finding of differences between the pharmacological properties of the PBBS studied in various systems is that the PBBS may comprise two or more different sites. We do not disagree with the need for a new nomenclature, but we are reluctant to assign a single new name to the PBBS until it is more certain that it represents a single binding site.
The isoquinoline derivative PK 11 195 appears to be superior to the benzodiazepine Ro5-4864 for imaging the PBBS in human gliomas. While this study was in progress, Bergstrom and colleagues reported that { 11C}R~5-4864 did not achieve hgher radioactivity in human gliomas than in brain, in agreement with our findings 1241. Our findings on surgically removed specimens of glioma also agree with the results on specimens of glioma obtained at autopsy [lG] . With our ['lC)PK 11 195 imaging studies, the strong correlations observed between specific activity and tumor radioactivity suggest that most of the binding sites are occupied at the lower specific activities, and this finding supports the view that the increased radioactivity in tumor is due to high-affinity binding to the PBBS. In the 5 patients studied at lower speclfic activity, the peak amount of PK 11195 in tumor (3.3-15.0 nmol/ 1,000 cm3> is similar to the dissociation constant ( K d ) of the PBBS, which has been estimated at 0.8 to 15.8 nM in human brain tissue and in gliornas 114, 16, 251; thus, the amount of unlabeled PK 11195 present in tumor in these cases may have been enough to occupy most of the PBBS, resulting in decreased binding of {l1C}PK 11195. Scans at higher specific activities may yield greater contrast between tumor and brain than that reported here. Our findings of high {"C}PK 11 195 radioactivity in a non-contrast-enhancing glioma and of nearly equal K1 values in tumor and remote gray matter indicate that disruption of the blood-brain barrier is not the basis for the positive imaging results.
The density of PBBS has been shown to be increased in lesions characterized by reactive ghosis and phagocytosis, including excitotoxic lesions and infarcts in animals {12, 13,261 and infarcts and multiple sclerosis plaques in humans {17). The binding observed in our in vitro study and the accumulation in our PET study may be due to the high density of astrocytes in gliomas or to increased expression of the binding site in &omas. It is unlikely that reactive gliosis adjacent to the tumors and phagocytosis in the tumors are responsible because ligand binding to PBBS is high in cultured glioma cells and in tumor regions densely populated with viable tumor cells [15, 161 and because ligand binding to PBBS is absent or low in pheochromocytoma and neuroblastoma implanted in rat brain Cl51. If scans with PBBS ligands such as ["C}PK 11 195 demonstrate increased radioactivity in non-neoplastic lesions with reactive ghosis, then such scans could prove diagnostically useful in such conditions. Scans with {llC)PK 11195 or other PBBS ligands may still be able to differentiate gliomas from reactive ghosis because the density of PBBS appears to be signlficantly greater in ghomas than in reactive gliosis [ 171. Furthermore, it is not known whether the pharmacological properties of the PBBS on reactive glia are similar to those we observed in gliomas, but if they are different, imaging with two different radiolabeled PBBS ligands might provide an approach for differentiating ghomas from reactive gliosis.
Scans with ["C}PK 11 195 or another radiolabeled PBBS llgand may prove useful in several ways in the diagnosis and management of gliomas. Potentially, they could prove valuable for distinguishing ghomas from other types of tumors and for predicting the prognosis of the patient. By showing the full extent of the tumor, such scans could be useful for guiding surgical resection or biopsy and for planning radiotherapy. Such scans might be used to distinguish viable from necrotic tumor and to assess the response of the tumor to treatment. Scans demonstrating PBBS may be possible using radioiodinated derivatives of PK 11 195 and single photon tomography 127, 281, and such scans could be performed at centers lacking facilities for PET.
